Please note this conference is being recorded. I will now turn the conference over to your host, Trip Taylor, with Investor Relations. You may begin. Thank you, Operator. I'd like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems' future financial and operating results and plans for developing and marketing new products. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these statements, including the risks and uncertainties described in T2 Biosystems' annual report on Form 10-K filed with the SEC on April 1, 2024, and other filings the company makes with the SEC from time to time. The company undertakes no obligation to publicly update or revise any forward-looking statements except as required by law. With that, I'd like to turn the call over to Chairman and CEO John Sperzel. John? Thank you all for joining our third quarter 2024 results call. I'll start by discussing our recent highlights and providing an update on the progress across our three corporate priorities before turning the call over to John Sprague, our Chief Financial Officer, who will review our financial results. I will then provide closing remarks before opening the call for questions and answers. T2 Biosystems is focused primarily on sepsis, and I will remind everyone that sepsis continues to take an enormous human and economic toll. Sepsis is the leading cause of death in U.S. hospitals and claims the lives of approximately 350,000 Americans annually. Sepsis represents the leading cost of hospitalization in the United States, costing our healthcare system an estimated $62 billion annually. Lastly, sepsis is the leading cause of 30-day hospital readmission in the United States, with 19% of sepsis survivors rehospitalized within 30 days and 40% within 90 days. On previous earnings calls, I've described the limitations of blood culture-based diagnostics, which are the current standard of care for the management of patients suspected of sepsis. Relying on blood culture as a clinical specimen for patients at risk of sepsis represents several challenges, including poor sensitivity, which can lead to false negative results or missed infections, and slow time to results, typically one to five days. Despite these shortcomings, blood culture remains as the standard of care for patients at risk of sepsis. Except for T2 Biosystems' sepsis products, all other FDA-cleared products authorized for pathogen detection or antibiotic resistance testing require a positive blood culture as the clinical specimen. These blood culture-dependent diagnostic products, which include virtually all of our competitors in this space, provide little to no clinical value if blood culture yields a false negative result due to poor sensitivity or if blood culture is not available due to supplier issues. The recent BD BACTEC blood culture supply interruption, which led to customer letters from the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention, or CDC, and resulted in blood culture media bottles being added to the medical device shortage list, underscores the risk of creating guidelines based on a single diagnostic technology that is blood culture. We believe this is the perfect time to lobby for changes to the guidelines to include diagnostic products that are able to detect bacterial and fungal pathogens and antibiotic resistance genes directly from blood, independent of blood culture, and we are actively lobbying for such changes. In response to this critical supply situation, a manuscript titled, "Changing the Culture of Blood Culture," was recently published in The Lancet, a world-leading medical journal. It highlights the potential for culture-independent diagnostics like the T2 Bacteria Panel, the T2 Candida Panel, and the T2 Resistance Panel to complement and improve the existing protocols for patients suspected of sepsis. T2 Biosystems has developed and is commercializing a technology that is designed to address the challenges associated with the other diagnostics used to detect sepsis-causing pathogens and antibiotic resistance. We provide the only FDA-cleared diagnostics able to detect sepsis-causing pathogens directly from whole blood without the need to wait days for a positive blood culture. The combination of our FDA-cleared T2Dx instrument, T2 Bacteria Panel, and T2 Candida Panel can detect sepsis-causing bacterial and fungal pathogens in three to five hours directly from blood. No other company in the world can make that claim. It's important to note that our expanded T2 Bacteria Panel, which now includes the detection of Acinetobacter baumannii, covers approximately 75% of all sepsis-causing bacterial pathogens commonly found in bloodstream infections. Likewise, our T2 Candida Panel covers approximately 90% of Candida species commonly found in bloodstream infections. Now turning to review the progress we have made across our three corporate priorities: accelerating our sales, enhancing our operations, and advancing our pipeline. Starting with our first corporate priority, accelerating our sales. In the U.S. market, our commercial team continues to prioritize increasing sales of our sepsis test panels. The T2 Biosystems team generated third-quarter revenue of $2.0 million, representing 34% growth compared to the prior year period. Growth was driven by $1.4 million of sepsis test panel revenue that included a 173% increase in the sales of T2 Bacteria Panel in the U.S. market. During the third quarter, we executed contracts for 11 T2Dx instruments, including one in the United States and 10 internationally. The international contracts helped drive a 78% increase in sales of the T2Dx instrument compared to the third quarter of 2023. To strengthen our U.S. commercialization efforts with our sepsis products and capitalize on what we believe is a significant opportunity to improve the standard of care, we are extremely pleased to have entered into an exclusive commercial distribution agreement with Cardinal Health. Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. Cardinal Health trades on the New York Stock Exchange under the symbol CAH, has annual revenue of more than $200 billion, has operations in more than 30 countries, and has approximately 48,000 employees. Cardinal Health is one of the largest healthcare companies in the United States and sells to 90% of U.S. hospitals through its extensive commercial organization and holds contracts with a large number of U.S. group purchasing organizations, or GPOs. Cardinal Health's reach includes the 200-plus children's hospitals in the United States, which we are now targeting following the recent T2 Candida Panel FDA clearance for use in pediatric patients. Our agreement grants Cardinal Health exclusive rights to the only FDA-cleared direct-from-blood pathogen detection products. In addition to the economic benefits, having access to T2 Biosystems' direct-from-blood diagnostics strengthens Cardinal Health's product offering to microbiology laboratories. We believe our agreement with Cardinal Health will be transformative, with the objectives of accelerated revenue growth and a faster path to profitability by expanding our access to the more than 6,000 U.S. hospitals. We expect the exclusive nature of the agreement to align interests and motivate the Cardinal commercial team and give Cardinal a competitive advantage vis-à-vis their competitors. While the terms of our agreement with Cardinal Health are confidential, in general, the economics and logistics are similar to those we have with our international distributors. For example, T2 Biosystems will sell our FDA-cleared products to Cardinal Health, including the T2Dx Instrument, the T2 Bacteria Panel, and the T2 Candida Panel, and Cardinal Health will sell these products to U.S. hospitals. We expect this collaboration to greatly expand our access to the U.S. hospital market as Cardinal Health has an extensive commercial and distribution infrastructure, including capital equipment specialists who will sell the T2Dx instrument. At this point, we have trained the team at Cardinal to fully understand the science behind our technology, its features and benefits, and the clinical and economic value it offers to customers. Our products are now established in the Cardinal Health ecosystem. They are in the process of launching the initial sales campaigns, and our teams have begun working together in the field. In the United States, we recently announced a co-marketing collaboration with Precision Inc., aimed at pioneering a new frontier in antibiotic stewardship to combat the growing threat of antimicrobial resistance. Antibiotic resistance is one of the greatest threats facing modern medicine, with millions of lives at risk. Over 1.27 million deaths are reported annually due to antimicrobial resistance, or AMR, which threatens to render essential antibiotics useless. The stakes are high, and time is critical. Each hour of delayed targeted treatment can increase the risk of death by up to 8% for sepsis patients. Precision is a New York-based private company that is leveraging two decades of expertise in antibiotic development to create a real-time AI-powered decision support platform. The product, also called Precision, is integrated with electronic health records, for example, Epic and Cerner, and provides clinicians with ranked, evidence-based antibiotic regimens tailored to each patient's needs. This approach can potentially stop antibiotic misuse, break the cycle of resistance, reduce healthcare costs, and ultimately save lives. We believe that artificial intelligence, or AI, will have an important and increasing role in healthcare delivery, and specifically in the management of patients at risk of sepsis. AI can be used to diagnose diseases, develop personalized treatment plans, and assist clinicians with decision-making. At T2 Biosystems, we have been searching for an AI-powered decision support platform to combine with our rapid direct-from-blood diagnostics. The Precision platform is designed to leverage data from diagnostics, such as our T2Dx instrument and test panels, to provide another level of precision using advanced pharmacokinetic models, pathogen profiles, and real-time patient data to enable clinicians to prescribe the right drug, right dose, and right duration as the patient's condition evolves. The platform adapts continuously to changing clinical information, providing ranked, evidence-based treatment regimens that help clinicians optimize care and improve outcomes. By combining our direct-from-blood diagnostics with the AI-driven Precision platform, we believe we can empower clinicians with the information to stop infections in their tracks faster than ever before. Beyond improving patient care, this collaboration is intended to drive product adoption and create exciting opportunities for growth in a rapidly evolving market. With speed and accuracy at its core, we believe the combined solution can provide hospitals with a powerful tool to improve outcomes and reduce costs. We're really excited about our new initiatives with Cardinal Health and Precision, and we believe each will contribute meaningfully to revenue in 2025 and beyond. In international markets, we continue to execute on our plan to expand our commercial footprint by entering into territory-exclusive distribution agreements to market and sell our products, including the T2Dx Instrument, the T2 Bacteria Panel, the T2 Candida Panel, and the T2 Resistance Panel. During the third quarter, we entered into new distribution agreements covering Malaysia and Indonesia. As indicated by our executed international instrument contracts, this expansion is already proving valuable. Outside of sepsis, we're making progress toward commercialization of our T2 Biothreat Panel and T2 Lyme Panel. We're identifying strong potential government targets and fielding interest to procure the T2 Biothreat Panel. We've presented to multiple U.S. government agencies organized by the Administration for Strategic Preparedness and Response, or ASPR, and have ongoing discussions with leading biothreat response laboratories in the United States regarding their interest in the T2 Biothreat Panel. We believe the unique attributes of the T2 Biothreat Panel, covered with it being the only FDA-cleared multi-target biothreat panel developed and manufactured in the United States, will be of interest under the new administration. Finally, we maintain our plan to launch the T2 Lyme Panel as a laboratory-developed test, or LDT, and we anticipate initiating commercialization by the start of the 2025 fiscal year. Moving to our second corporate priority: enhancing our operations. Operationally, we have converted approximately 80% of our debt to common stock over the past 12 to 18 months, which strengthens our balance sheet and significantly reduces our quarterly interest payments. We're focused on strengthening our cash position and making further improvements to our cost structure. As you'll see in our 10-Q filing, we have used our at-the-market, or ATM, facility intermittently to raise capital during the third quarter and early fourth quarter of 2024. We're continuing to explore other sources of capital, and we are actively engaged with potential strategic investors or partners. During the third quarter of 2024, we began partnering with ADP Total Source as our Professional Employer Organization, or PEO, to provide comprehensive and cost-effective HR solutions, including healthcare benefits, workers' compensation, payroll and tax support, and HR guidance. We expect this change to result in annualized savings of at least $400,000. During the third quarter of 2024, we reduced our inventory by leveraging our new Oracle ERP system to drive better demand planning and material management. We believe the Oracle ERP expansion will continue to favorably impact inventory levels, cost of goods sold, and ultimately improve cash flow. Finally, in the first quarter of 2025, we plan to further consolidate our real estate space by exiting our facility at 4 Hartwell Avenue in Lexington, Massachusetts, and consolidating those operations into our headquarters at 101 Hartwell Ave in Lexington, Massachusetts. We expect this action to reduce our facility's cost by approximately $1 million annually. Moving to our third corporate priority: advancing our pipeline. Our pipeline initiatives are focused on expanding the test menu for our T2Dx Instrument. There are four test expansion programs in our pipeline, including the U.S. T2 Resistance Panel, the T2 Lyme Panel, the expanded T2 Candida Panel to include detection of Candida auris, and the expanded T2 Bacteria Panel to include a claim for pediatric testing. Three of these programs have already received FDA Breakthrough Device Designation, including the T2 Resistance Panel, the T2 Lyme Panel, and the Candida auris test, which should provide for a straightforward path to market and help solve an unmet need for rapid detection of these respective target biomarkers. The U.S. T2 Resistance Panel is a CE-marked diagnostic test able to detect antibiotic resistance genes directly from blood in just three to five hours. The T2 Resistance Panel simultaneously detects 13 antibiotic resistance genes from both Gram-positive and Gram-negative bacterial pathogens. The T2 Resistance Panel is marketed and sold in Europe under a CE mark, and as I mentioned earlier, has received breakthrough device designation, which will provide for a prioritized 510(k) review process. We expect to submit the T2 Resistance Panel to the FDA during the first quarter of 2025. This one-quarter delay is due to our decision to prioritize manufacturing products for current and new customers ahead of manufacturing the T2 Resistance Panel cartridges for internal R&D testing. The T2 Lyme Panel is a direct-from-blood molecular diagnostic test designed for the early detection of Borrelia burgdorferi, the bacterium that causes Lyme disease in the United States. Lyme disease is the leading vector-borne disease in America, with an estimated 3.4 million tests performed each year. The current diagnostic product process is a two-tiered antibody test algorithm that relies on the presence of antibodies and can only be used accurately four to eight weeks after infection. If left untreated, the bacteria may spread throughout the body and become much harder to eradicate and treat effectively. Although symptoms of Lyme disease are similar to flu, Borrelia burgdorferi infections can lead to chronic, debilitating disease. To address this clinical unmet need, we have developed an extremely sensitive diagnostic for the detection of early Lyme disease with an analytical sensitivity that is in line with our FDA-cleared sepsis tests. We have recently completed clinical studies required to launch the T2 Lyme Panel as a laboratory-developed test, or LDT. We believe our test will detect Lyme disease within the first 30 days post-infection compared to antibody tests that can take 30 to 60 days post-infection. The expanded T2 Candida Panel, which will include the detection of Candida auris, is a direct-from-blood molecular diagnostic test designed to detect Candida species in just three to five hours without the need to wait days for a positive blood culture. We believe the addition of Candida auris detection will strengthen the value proposition of our T2 Candida Panel and lead to increased adoption. Candida auris is a multi-drug-resistant fungal pathogen that has a mortality rate of up to 60% and is recognized as a serious global health threat by the CDC and the World Health Organization. The CDC estimates that costs associated with U.S. fungal diseases are as high as $48 billion annually and has called on public health professionals to help lower the burden of fungal disease by continuing to raise awareness of the lifesaving benefits of early detection and proper treatment. A 2022 Journal of Clinical Microbiology study conducted at the Bambino Gesù Hospital in Rome, Italy, found that pediatric patients suspected of fungal bloodstream infections that were tested with the T2 Candida Panel receive species identification results 121.8 hours faster compared to blood culture-based diagnostics. The expanded T2 Bacteria Panel to include a claim for pediatric testing. We expect to submit a 510(k) pre-market notification to the FDA to expand the use of our T2 Bacteria Panel to include pediatric testing in 2025. With that, I'll now turn the call over to John Sprague to provide a detailed update on our first quarter financial results. John? Thank you, John. Third quarter 2024 revenues were $2 million, all from sepsis product sales, a 34% increase from the prior year period. International instrument sales increased 78%, and sepsis test sales increased 34% compared to the prior year period. Second quarter 2024 cost of product revenues were $4.1 million, a 4% increase compared to the prior year period driven by increased international instrument and sepsis test sales. Research and development expenses were $2.7 million, comparable to the prior year period. Selling general administrative expenses were $5.4 million, a 10% decrease compared to the prior year period driven by decreased headcount offset by increased legal expenses. The third quarter 2024 net loss was $10.1 million, $0.57 per share compared to the prior year third quarter net loss of $15.4 million, $3.45 per share. Cash and cash equivalents were $2.1 million as of September 30, 2024. We raised $4.3 million in net proceeds with our ATM during the quarter and $3.2 million since September 30, 2024. As we announced last week, the company received a notice from NASDAQ on November 7, 2024, indicating that the company's market value had been trading below listing requirements. We have appealed the notice and expect to put forth a plan of compliance to NASDAQ. We expect fourth quarter 2024 total sepsis and product revenues of $2.5 million-$3.5 million. This target does not include potential sales of T2 Biothreat or T2 Lyme tests. Thank you, and back to John Sperzel for closing remarks. Thank you, John. We are very encouraged by our progress made in the third quarter of 2024 compared to the prior year period, including total revenue growth of 34%, sepsis test panel growth of 34%, U.S. T2 Bacteria Panel growth of 173%, and T2Dx instrument growth of 78% internationally. Moving forward, we're excited by the potential to accelerate the growth of our sepsis business in the United States through the exclusive commercial agreement with Cardinal Health and the co-marketing agreement with Precision. Our new product pipeline is rich with potential catalysts that have already received FDA breakthrough device designation, including the T2 Resistance Panel, which we plan to submit to the FDA for 510(k) clearance during the first quarter of 2025, the T2 Lyme Panel, the expanded T2 Candida Panel to include the detection of Candida auris, and the expanded T2 Bacteria Panel to include a claim for pediatric testing. With that, I'd like to turn the call back over to the operator to open the line for questions. Operator? At this time, we will be conducting a question-and-answer session. If you would like to ask a question, please press Star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press Star 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the Star keys. One moment, please, while we poll for questions. From our participants, we have Yi Chen with H.C. Wainwright. Thank you for taking my questions. Just have a few questions regarding the partnership with Cardinal Health. Has Cardinal Health already started marketing T2 Biosystems products? And do you expect the effects to show in the fourth quarter financials? And a follow-up question is, in the third quarter, out of the 11 instruments executed, you have one in the U.S. Do you expect the partnership with Cardinal Health to shift the instrument executed to be more in the U.S. than internationally? Thank you. Yeah, thanks for the question. So let me just take the second two parts of that question. One, we absolutely expect the relationship with Cardinal to increase our instrument and consumable sales in the United States. We have begun the marketing with Cardinal Health. And I just want to add a little bit more color around maybe the why behind a partnership with Cardinal, which we're certainly excited about. As you know, there are over 6,000 hospitals in the U.S. We believe every one of them should have a T2Dx Instrument and be using our tests. But as a small company with limited resources, it's pretty difficult for us to reach them alone. And so to address that, we have been searching for a partner with a number of characteristics that we found in Cardinal. One would be a partner with a significant presence in U.S. hospitals, a large commercial organization, and a strong balance sheet because we think that translates into credibility from a customer perspective. As I mentioned earlier, Cardinal is one of the largest healthcare companies in the United States. They have over $2 billion in annual sales. They sell to over 90% of U.S. hospitals, and they have broad GPO contracts. So they are a trusted partner of U.S. hospitals. Second, we were looking for a partner with a strong presence in U.S. hospital microbiology labs, as we think that translates into important customer relationships, which we've already seen with Cardinal throughout the training and early stages of marketing together. For example, within the first week of training the Cardinal folks, Cardinal has already set up a meeting with a 20-plus hospital system. We never would have been able to get in front of that system on our own. And then lastly, we were looking for a partner that wanted our products within their portfolio. We know that our products are highly differentiated, but we wanted a partner that was sort of hungry to have them within their portfolio. And we saw that in Cardinal. And they certainly understand that exclusive rights to our products provide differentiation for them vis-à-vis their competitors. So sort of all those three reasons are why we chose Cardinal. We're certainly excited about it. We think it's going to have a significant impact in 2025, and it may impact 2024. We have about six weeks left in the quarter. Got it, and a question regarding the LDT. Is that something we should expect to see have a contribution to the top line revenue in the first half of 2025? That's our plan. The Lyme season typically starts, I mean, starting earlier and earlier each year. Historically, it's kind of started around the April, May timeframe. So I think sometime in the latter half of second quarter is when we're targeting to launch that as an LDT. Got it. Thank you. Thank you, Yi. We have reached the end of our question-and-answer window, and at this time, I would like to see if management has any closing remarks. I'd like to thank you all for participating in our Q3 earnings call and look forward to updating on our next call. Okay. This does conclude today's conference call, and you may disconnect your lines at this time. Thank you for your participation.